Skip to main content
Products & servicesFCA PRIN 2A.35 min read

Consumer Duty distribution chain rules for smaller UK brokers and intermediaries

How smaller FCA-regulated brokers, IFAs, and intermediaries manage PRIN 2A.3 manufacturer and distributor duties, target markets, fair value data, and harm escalation.

Calm UK advisory desk with forest-green notebook, brass pen, and teacup in morning light

Retail financial products rarely move straight from a single provider to an end consumer without intermediaries. Mortgages, general insurance policies, investment wrappers, and credit agreements regularly pass through networks, packagers, managing general agents, IFAs, and brokers. Under FCA PRIN 2A.3, every firm along that distribution chain holds clear accountability for customer outcomes, yet smaller intermediaries regularly stumble by assuming that product governance rests solely with the large bank, insurer, or platform sitting at the top of the chain.

The essential starting point for any smaller firm is verifying whether it operates strictly as a distributor or crosses into co-manufacturer territory. Under PRIN 2A.3 and aligned PROD rules, a firm acts as a manufacturer whenever it creates, designs, operates, or underwrites a product, or exercises material control over core features such as target market, risk structure, or overall pricing. Several smaller firms assume they are pure distributors until an audit reveals they construct in-house model investment portfolios, bundle bespoke insurance add-ons, or negotiate white-label credit schemes. Classifying each product line accurately determines every subsequent governance obligation.

Manufacturers must establish a sufficiently granular target market for every product, define the negative target market for whom the product is unsuitable, carry out scenario testing across different customer groups, and publish clear summaries allowing distributors to understand product features and fair value conclusions. Whenever a smaller wealth firm or specialist broker co-manufactures a proposition alongside an insurer or platform, a short written agreement should assign clear ownership for ongoing testing, fair value updates, and regulatory notifications so critical duties never fall between two parties.

Pure distributors hold equally concrete duties under PRIN 2A.3.12R to PRIN 2A.3.20R. Before arranging or recommending a product, a distributor must obtain and genuinely review the manufacturer's target market statement, intended distribution strategy, and fair value summary. Saving unread provider PDFs in a shared folder fails the rule completely. Brokers and advisers must verify that their actual client cohort fits the stated target market, check that sales and servicing channels accommodate FG21/1 capability or access needs, and confirm that adding the firm's own adviser fee or broker commission still leaves fair value intact.

Chasing overdue or overly generic packs from large providers remains one of the sharpest daily frustrations for smaller UK intermediaries. When a manufacturer supplies vague marketing language instead of usable target market criteria or fair value conclusions, the distributor should request clarification politely in writing, record follow-up dates, and escalate unresolved gaps to its own directors. Continuing to place new business indefinitely without basic target market or fair value data leaves the intermediary directly exposed under PRIN 2A.3 regardless of the provider's size.

Distribution-chain duties flow upwards as well as downwards. Under PRIN 2A.3.16R and the cross-cutting rule to avoid foreseeable harm, distributors must share requested sales and outcome information back with manufacturers and proactively report recurring problems they observe on the ground. An IFA spotting repeated transfer delays harming bereaved spouses on a particular platform, or a broker seeing regular claims declines caused by unclear insurer exclusions, should send a formal written harm notice upstream and track the provider's response.

Occasionally a smaller intermediary concludes that a provider's product no longer delivers fair value or creates persistent servicing detriment, yet the manufacturer declines to fix the issue. Consumer Duty does not allow a distributor to keep selling a harmful product merely because clients recognise the brand or commission terms look attractive. Directors must evaluate suspending new business placements, consider whether existing affected clients need proactive contact, record the rationale clearly in governance minutes, and weigh a Principle 11 notification to the FCA where serious unresolved harm persists.

Customers in vulnerable circumstances face heightened risk whenever distribution chains fragment responsibility. A client may share a serious medical diagnosis, hearing loss, or recent bereavement with a trusted local broker or adviser, only for the underlying lender or insurer to send dense automated notices because adjustments never crossed the handover. After obtaining explicit UK GDPR consent, smaller intermediaries should document exactly which communication or support preferences were transmitted to the product provider and verify that downstream correspondence reflects those needs.

Proportionate distribution-chain oversight does not require enterprise supplier portals. Maintain a clean product and provider register listing each active and closed product, the firm's exact role as distributor or co-manufacturer, the review date of the latest manufacturer fair value and target market pack, any pending provider chases, and any upstream harm reports raised. Review the register every six months ahead of the annual PRIN 2A.8 board report. No register guarantees FCA compliance by itself; active target market checks, fee impact scrutiny, and timely upstream escalation show PRIN 2A.3 working properly.

Frequently Asked Questions

Practical answers for UK regulated firms

6 questions
1When does a smaller IFA or broker count as a co-manufacturer under PRIN 2A.3?

A firm counts as a co-manufacturer when it plays a decision-making role in designing core product features, target market criteria, or overall pricing, such as building bespoke model portfolios or co-designing white-label insurance schemes.

2What should a small distributor do when a large manufacturer sends vague fair value packs?

Send a polite written request specifying the missing target market or fair value details, log the chase dates, escalate persistent gaps to directors, and decide whether continuing to place new business remains defensible under PRIN 2A.3.

3Are distributors required to send management information back to manufacturers?

Yes. Under PRIN 2A.3.16R, distributors must provide relevant sales, distribution, and outcome information when reasonably requested by manufacturers, and proactively alert manufacturers whenever they identify customer harm or sales outside the target market.

4Can a small intermediary pass a client's vulnerability adjustments to a lender or insurer?

Yes, provided the intermediary explains clearly why sharing helps deliver consistent support and records the customer's explicit consent under UK GDPR before transmitting sensitive personal details across the distribution chain.

5What is a negative target market and why does it matter to smaller brokers?

A negative target market identifies customer groups for whom a product is unsuitable or likely to cause harm. Checking clients against negative target market criteria prevents mis-selling and flags where distribution must stop.

6How often should smaller firms review their product and provider distribution register?

Reviewing the register every six months, and immediately whenever a provider issues updated fair value packs or complaint trends spike, keeps distribution governance current without creating excessive administration.

Related reading